查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1671195

基因治療的全球市場:市場規模·佔有率·趨勢，產業分析 (各治療領域·媒介類別·方法·各給藥途徑·各地區)，未來預測 (2025年～2034年)

Gene Therapy Market Size, Share, Trends, Industry Analysis Report: By Therapeutic Area, Vector Type, Approach, Route of Administration, and Region - Market Forecast 2025-2034
出版日期: | 出版商: Polaris Market Research | 英文 154 Pages | 商品交期: 最快1-2個工作天內

價格

根據 Polaris Market Research 的最新研究，基因治療市場預計到 2034 年將達到 272.502 億美元。該報告對當前的市場動態提供了詳細的見解，並對未來的市場成長進行了分析。

基因治療涉及糾正或替換患者細胞中的不健康基因以治療或預防疾病。基因工程的快速發展以及對分子生物學認知的不斷加深，推動了基因治療從實驗階段走向實際臨床應用。研究人員和生物製藥公司正在大力投資開發安全有效的治療方法，而監管機構正在簡化審批流程，以加速基因治療市場的擴張。

由於杜氏肌肉營養不良症 (DMD)、鐮狀細胞病、血友病和囊性纖維化等遺傳疾病的盛行率不斷上升，對基因治療的需求正在迅速增加。與專注於症狀管理的傳統治療不同，基因療法從基因層面針對這些疾病的根本原因。這種有針對性的方法提高了治療效果，並有可能帶來長期甚至永久的緩解。近年來，CRISPR-Cas9 和鋅指核酸酶 (ZFN) 等基因編輯技術的顯著進步使得基因修飾更加精確和高效。

越來越多的基因療法監管部門批准正在推動基因治療市場的成長。美國食品藥物管理局 (FDA) 和歐洲藥品管理局 (EMA) 等政府機構已經認識到這些治療方法的變革潛力。這些機構加快了有前途的候選人的審批流程。 Zolgensma 治療脊髓性肌肉萎縮症 (SMA) 和 Luxturna 治療遺傳性視網膜疾病等療法取得了顯著的臨床成功，為更廣泛地應用基因為基礎的療法和程序鋪平了道路。

基因治療市場：概述

基於治療領域，腫瘤疾病領域將在 2024 年引領基因治療市場佔有率，因為腫瘤疾病的流行及其治療對身體和心理產生重大影響。

根據載體類型，病毒部分在基因治療市場收入佔有率中處於領先地位，因為它可以有效且有效率地將基因傳遞到針對各種癌症、單基因疾病和傳染病的目標細胞中。

北美憑藉其強大的研究基礎設施、先進的醫療保健系統、大量的臨床試驗資金以及由 FDA 領導的支持性監管框架引領基因治療市場，從而實現新型基因療法的快速開發和批准。

全球主要公司包括abeona·serapyutikku，諾華AG，火花·serapyutikusuLLC，giriado·saienshizu，布里斯托爾·maiyazu·Squibb，adobaumu·baiotekunorojizu，arunairamu·famashutikaruzu，美國的·gene·tekunorojizu，apuraido·jenetikku·tekunorojizu·團體，baiojen，urutorajenikkusu等舉出(舉行)。

目錄

第1章 簡介

第2章 摘要整理

第3章 分析方法

第4章 基因治療市場洞察

  • 基因治療:產業概要
  • 基因治療的市場動態
    • 促進因素和機會
      • 增加基因治療開發的審批和投資
      • 目標疾病的傳播
      • 老年人口增加
    • 阻礙因素和課題
      • 製造與物流課題
      • 治療成本高，監管架構不明確
      • 缺乏醫療基礎設施
  • 波特的五力分析
    • 供應商談判力 (高)
    • 新加入企業的威脅 (低)
    • 買主談判力 (中)
    • 替代產品的威脅 (低)
    • 企業間競爭 (高)
  • 大環境分析
  • COVID-19影響分析與產業趨勢

第5章 基因治療市場:各治療領域的評估

  • 簡介
  • 自體免疫疾病
  • 心血管疾病
  • 皮膚疾病
  • 血液疾病
  • 代謝障礙
  • 肌肉相關疾病
  • 腫瘤性疾病
  • 其他的治療領域

第6章 基因治療市場:媒介的不同種類的評估

  • 簡介
  • 病毒
    • 反轉錄病毒載體
      • 伽馬反轉錄病毒載體
      • 慢病毒載體
    • 腺結合病毒媒介
    • 其他的病毒載體
  • 非病毒性
    • 寡核甘酸
    • 其他的非病毒載體

第7章 按基因治療市場:方法的評估

  • 簡介
  • 遺傳基因增強
  • 腫瘤溶解性病毒療法
  • 免疫療法
  • 其他的方法

第8章 基因治療市場:各給藥途徑的評估

  • 簡介
  • 關節內
  • 小腦內
  • 皮內
  • 肌肉內
  • 腫瘤內
  • 靜脈內
  • 膀胱內
  • 玻璃體內
  • 視網膜下
  • 其他

第9章 基因治療市場:各地區的評估

  • 簡介
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 奧地利
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
  • 南美
    • 巴西
    • 墨西哥
  • 中東·非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第10章 競爭情形

  • 主要打入市場企業:分類
  • 策略性架構
  • 業者情勢
  • 策略的分類
    • 事業聯盟/事業合作/契約
    • 擴張/合併/收購
    • 產品開發/新銷售

第11章 企業簡介

  • Sangamo Biosciences
  • Voyager Therapeutics
  • Ultragenyx
  • GlaxoSmithKline
  • Gilead Sciences Inc
  • Bristol Myers Squibb
  • Novartis AG
  • Spark Therapeutics LLC
  • Bluebird Bio
Product Code: PM1084

The gene therapy market size is expected to reach USD 27,250.20 million by 2034, according to a new study by Polaris Market Research. The report "Gene Therapy Market Size, Share, Trends, Industry Analysis Report: By Therapeutic Area (Autoimmune Disorders, Cardiovascular Diseases, Dermatological Disorders, Hematological Disorders, Metabolic Disorders, Muscle-Related Diseases, Oncological Disorders, and Others), Vector Type, Approach, Route of Administration, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Gene therapy involves modifying or replacing unhealthy genes within a patient's cells to treat or prevent disease. Rapid advancements in genetic engineering, along with an increasing understanding of molecular biology, have propelled gene therapy from experimental stages to real-world clinical applications. Researchers and biopharmaceutical companies are investing heavily in developing safe and effective therapies, while regulatory bodies are streamlining approval processes to accelerate gene therapy market expansion.

The demand for gene therapy has surged due to the increasing prevalence of genetic disorders such as Duchenne muscular dystrophy (DMD), sickle cell disease, hemophilia, and cystic fibrosis. Unlike traditional treatment methods that primarily focus on symptom management, gene therapy targets the underlying cause of these diseases at the genetic level. This targeted approach enhances treatment efficacy and offers the potential for long-term or even permanent relief. In recent years, significant breakthroughs in gene-editing technologies, such as CRISPR-Cas9 and zinc finger nucleases (ZFNs), have enabled more precise and efficient gene modifications.

The rising number of regulatory approvals for gene-based treatments is propelling the gene therapy market growth. Government agencies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have recognized the transformative potential of these therapies. They are expediting the approval process for promising candidates. Therapies such as Zolgensma for spinal muscular atrophy (SMA) and Luxturna for inherited retinal disease have demonstrated remarkable clinical success, paving the way for broader adoption of gene-based therapies or treatments.

Gene Therapy Market Report Highlights

Based on therapeutic area, the oncological disorders segment leads the gene therapy market share in 2024 due to the prevalence of significant physical and psychological impacts of the disease and its treatment.

By vector type, the viral segment leads gene therapy market revenue share due to its effective and efficient delivering genes to the targeted cells for various cancers, monogenic and infectious diseases.

North America leads the gene therapy market due to its robust research infrastructure, advanced healthcare system, significant funding for clinical trials, and a supportive regulatory framework, particularly from the FDA, which allows for rapid development and approval of new gene therapies.

A few global key market players are Abeona Therapeutic, Novartis AG, Spark Therapeutics LLC, Gilead Sciences Inc., Bristol Myers Squibb, Adverum Biotechnologies, Alnylam Pharmaceuticals, American Gene Technologies, Applied Genetic Technologies Corporation, Biogen, and Ultragenyx.

Polaris Market Research has segmented the gene therapy market report on the basis of therapeutic area, vector type, approach, route of administration, and region:

By Type Therapeutic Area Outlook (Revenue, USD Million, 2020-2034)

  • Autoimmune Disorders
  • Cardiovascular Diseases
  • Dermatological Disorders
  • Hematological Disorders
  • Metabolic Disorders
  • Muscle-Related Diseases
  • Oncological Disorders
  • Others

By Vector Type Outlook (Revenue, USD Million, 2020-2034)

  • Viral
  • Non-Viral

By Approach Outlook (Revenue, USD Million, 2020-2034)

  • Gene Augmentation
  • Oncolytic Viral Therapy
  • Immunotherapy
  • Other Approaches

By Route of Administration Outlook (Revenue, USD Million, 2020-2034)

  • Intraarticular
  • Intracerebellar
  • Intradermal
  • Intramuscular
  • Intratumoral
  • Intravenous
  • Intravesical
  • Intravitreal
  • Subretinal
  • Others

By Regional Outlook (Revenue, USD Million, 2020-2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Rest of Asia Pacific
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

Chapter 1. Introduction

  • 1.1 Report Description
    • 1.1.1 Objectives of the Study
    • 1.1.2 Market Scope
    • 1.1.3 Assumptions
  • 1.2 Stakeholders

Chapter 2. Executive Summary

Chapter 3. Research Methodology

  • 3.1 Overview
    • 3.1.1 Data Mining
  • 3.2 Data Sources
    • 3.2.1 Primary Sources
    • 3.2.2 Secondary Sources

Chapter 4. Gene Therapy Market Insights

  • 4.1 Gene Therapy - Industry snapshot
  • 4.1 Gene Therapy Market Dynamics
    • 4.1.1 Drivers and Opportunities
      • 4.1.1.1 Rising Approval and Investments in Gene Therapy Development
      • 4.1.1.2 Growing Prevalence of Target Diseases
      • 4.1.1.3 Growing Geriatric Population Base
    • 4.1.2 Restraints and Challenges
      • 4.1.2.1 Manufacturing and logistics challenges
      • 4.1.2.2 High Procedure Costs and Presence of Ambiguous Regulatory Framework
      • 4.1.2.3 Lack of Healthcare Infrastructure
  • 4.2 Gene Therapy Market - Porter's Five Forces
    • 4.2.1 Bargaining Power of Suppliers (High)
    • 4.2.2 Threats of New Entrants: (Low)
    • 4.2.3 Bargaining Power of Buyers (Moderate)
    • 4.2.4 Threat of Substitute (Low)
    • 4.2.5 Rivalry among existing firms (High)
  • 4.3 Gene Therapy Market - PEST Analysis
  • 4.4 Covid-19 Impact Analysis & Industry Trends

Chapter 5. Gene Therapy Market Assessment by Therapeutic Area

  • 5.1 Introduction
  • 5.2 Autoimmune Disorders
  • 5.3 Cardiovascular Diseases
  • 5.4 Dermatological Disorders
  • 5.5 Hematological Disorders
  • 5.6 Metabolic Disorders
  • 5.7 Muscle-related Diseases
  • 5.8 Oncological Disorders
  • 5.9 Other Therapeutic Areas

Chapter 6. Gene Therapy Market Assessment by Vector Type

  • 6.1 Introduction
  • 6.2 Viral
    • 6.2.1 Retroviral vectors
      • 6.2.1.1 Gamma-retroviral vectors
      • 6.2.1.2 Lentiviral vectors
    • 6.2.2 Adeno-associated virus vectors
    • 6.2.3 Other viral vectors
  • 6.3 Non-Viral
    • 6.3.1 Oligonucleotides
    • 6.3.2 Other non-viral vectors

Chapter 7. Gene Therapy Market Assessment by Approach

  • 7.1 Introduction
  • 7.2 Gene Augmentation
  • 7.1 Oncolytic Viral Therapy
  • 7.2 Immunotherapy
  • 7.3 Other Approaches

Chapter 8. Gene Therapy Market Assessment by Route of Administration

  • 8.1 Introduction
  • 8.2 Intraarticular
  • 8.3 Intracerebellar
  • 8.4 Intradermal
  • 8.5 Intramuscular
  • 8.6 Intratumoral
  • 8.7 Intravenous
  • 8.8 Intravesical
  • 8.9 Intravitreal
  • 8.10 Subretinal
  • 8.11 Others

Chapter 9. Gene Therapy Market Assessment by Region

  • 9.1 Introduction
  • 9.2 Gene Therapy Market - North America
    • 9.2.1 Gene Therapy Market - U.S.
    • 9.2.2 Gene Therapy Market - Canada
  • 9.3 Gene Therapy Market - Europe
    • 9.3.1 Gene Therapy Market - Germany
    • 9.3.2 Gene Therapy Market - UK
    • 9.3.3 Gene Therapy Market - France
    • 9.3.4 Gene Therapy Market - Italy
    • 9.3.5 Gene Therapy Market - Spain
    • 9.3.6 Gene Therapy Market - Netherlands
    • 9.3.7 Gene Therapy Market - Austria
  • 9.4 Gene Therapy Market - Asia Pacific
    • 9.4.1 Gene Therapy Market - China
    • 9.4.2 Gene Therapy Market - India
    • 9.4.3 Gene Therapy Market - Japan
    • 9.4.4 Gene Therapy Market - South Korea
  • 9.5 Gene Therapy Market - Latin America
    • 9.5.1 Gene Therapy Market - Brazil
    • 9.5.2 Gene Therapy Market - Mexico
  • 9.6 Gene Therapy Market - Middle East & Africa
    • 9.6.1 Gene Therapy Market - Saudi Arabia
    • 9.6.2 Gene Therapy Market - UAE

Chapter 10. Competitive Landscape

  • 10.1 Key Market Players: Categorization
  • 10.2 Strategy Framework
  • 10.3 Vendor Landscape
  • 10.4 Strategies Categorization
    • 10.4.1 Partnerships/Collaborations/Agreements
    • 10.4.2 Expansions/Mergers/Acquisitions
    • 10.4.3 Product Development/New Launch

Chapter 11. Company Profiles

  • 11.1 Sangamo Biosciences
    • 11.1.1 Business Overview
    • 11.1.2 Financial Snapshot
    • 11.1.3 Products and Services
    • 11.1.4 Recent Developments
  • 11.2 Voyager Therapeutics
    • 11.2.1 Business Overview
    • 11.2.2 Financial Snapshot
    • 11.2.3 Products and Services
    • 11.2.4 Recent Developments
  • 11.3 Ultragenyx
    • 11.3.1 Business Overview
    • 11.3.2 Financial Snapshot
    • 11.3.3 Products and Services
    • 11.3.4 Recent Developments
  • 11.4 GlaxoSmithKline
    • 11.4.1 Business Overview
    • 11.4.2 Financial Snapshot
    • 11.4.3 Products and Services
    • 11.4.4 Recent Developments
  • 11.5 Gilead Sciences Inc
    • 11.5.1 Business Overview
    • 11.5.2 Financial Snapshot
    • 11.5.3 Products and Services
    • 11.5.4 Recent Developments
  • 11.6 Bristol Myers Squibb
    • 11.6.1 Business Overview
    • 11.6.2 Financial Snapshot
    • 11.6.3 Products and Services
    • 11.6.4 Recent Developments
  • 11.7 Novartis AG
    • 11.7.1 Business Overview
    • 11.7.2 Financial Snapshot
    • 11.7.3 Products and Services
    • 11.7.4 Recent Developments
  • 11.8 Spark Therapeutics LLC
    • 11.8.1 Business Overview
    • 11.8.2 Products and Services
    • 11.8.3 Recent Developments
  • 11.9 Bluebird Bio
    • 11.9.1 Business Overview
    • 11.9.2 Recent Developments
    • 11.9.3 Products and Services
    • 11.9.4 Recent Developments

List of Tables

  • Table 1 Global Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 1 Global Gene Therapy Market, by Autoimmune Disorders, 2020-2034 (USD Million)
  • Table 2 Global Gene Therapy Market, by Cardiovascular Diseases, 2020-2034 (USD Million)
  • Table 3 Global Gene Therapy Market, by Dermatological Disorders, 2020-2034 (USD Million)
  • Table 4 Global Gene Therapy Market, by Hematological Disorders, 2020-2034 (USD Million)
  • Table 5 Global Gene Therapy Market, by Metabolic Disorders, 2020-2034 (USD Million)
  • Table 6 Global Gene Therapy Market, by Muscle-related Diseases, 2020-2034 (USD Million)
  • Table 7 Global Gene Therapy Market, by Oncological Disorders, 2020-2034 (USD Million)
  • Table 8 Global Gene Therapy Market, by Other Therapeutic Areas, 2020-2034 (USD Million)
  • Table 9 Global Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 10 Global Gene Therapy Market, by Viral, 2020-2034 (USD Million)
  • Table 11 Global Gene Therapy Market, by Retroviral vectors, 2020-2034 (USD Million)
  • Table 12 Global Gene Therapy Market, by Gamma-retroviral vectors, 2020-2034 (USD Million)
  • Table 13 Global Gene Therapy Market, by Lentiviral vectors, 2020-2034 (USD Million)
  • Table 14 Global Gene Therapy Market, by Adeno-associated virus vectors, 2020-2034 (USD Million)
  • Table 15 Global Gene Therapy Market, by Other viral vectors, 2020-2034 (USD Million)
  • Table 16 Global Gene Therapy Market, by Non-Viral, 2020-2034 (USD Million)
  • Table 17 Global Gene Therapy Market, by Oligonucleotides, 2020-2034 (USD Million)
  • Table 18 Global Gene Therapy Market, by Other non-viral vectors, 2020-2034 (USD Million)
  • Table 19 Global Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 20 Global Gene Therapy Market, by Gene Augmentation, 2020-2034 (USD Million)
  • Table 21 Global Gene Therapy Market, by Oncolytic Viral Therapy, 2020-2034 (USD Million)
  • Table 22 Global Gene Therapy Market, by Immunotherapy, 2020-2034 (USD Million)
  • Table 23 Global Gene Therapy Market, by Other Approaches, 2020-2034 (USD Million)
  • Table 24 Global Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 25 Global Gene Therapy Market, by Intraarticular, 2020-2034 (USD Million)
  • Table 26 Global Gene Therapy Market, by Intracerebellar, 2020-2034 (USD Million)
  • Table 27 Global Gene Therapy Market, by Intradermal, 2020-2034 (USD Million)
  • Table 28 Global Gene Therapy Market, by Intramuscular, 2020-2034 (USD Million)
  • Table 29 Global Gene Therapy Market, by Intratumoral, 2020-2034 (USD Million)
  • Table 30 Global Gene Therapy Market, by Intravenous, 2020-2034 (USD Million)
  • Table 31 Global Gene Therapy Market, by Intravesical, 2020-2034 (USD Million)
  • Table 32 Global Gene Therapy Market, by Intravitreal, 2020-2034 (USD Million)
  • Table 33 Global Gene Therapy Market, by Subretinal, 2020-2034 (USD Million)
  • Table 34 Global Gene Therapy Market, by Others, 2020-2034 (USD Million)
  • Table 35 Gene Therapy Market Assessment, By Geography, 2020-2034 (USD Million)
  • Table 36 North America Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 37 North America Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 38 North America Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 39 North America Gene Therapy Market, By Retroviral Vector, 2020-2034 (USD Million)
  • Table 40 North America Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 41 North America Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 42 North America Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 43 U.S. Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 44 U.S. Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 45 U.S. Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 46 U.S. Gene Therapy Market, By Retroviral vectors, 2020-2034 (USD Million)
  • Table 47 U.S. Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 48 U.S. Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 49 U.S. Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 50 Canada Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 51 Canada Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 52 Canada Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 53 Canada Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 54 Canada Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 55 Canada Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 56 Canada Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 57 Europe Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 58 Europe Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 59 Europe Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 60 Europe Gene Therapy Market, By Retroviral vectors, 2020-2034 (USD Million)
  • Table 61 Europe Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 62 Europe Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 63 Europe Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 64 Germany Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 65 Germany Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 66 Germany Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 67 Germany Gene Therapy Market, By Retroviral Vector, 2020-2034 (USD Million)
  • Table 68 Germany Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 69 Germany Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 70 Germany Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 71 UK Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 72 UK Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 73 UK Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 74 UK Gene Therapy Market, By Retroviral vectors, 2020-2034 (USD Million)
  • Table 75 UK Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 76 UK Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 77 UK Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 78 France Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 79 France Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 80 France Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 81 France Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 82 France Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 83 France Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 84 France Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 85 Italy Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 86 Italy Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 87 Italy Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 88 Italy Gene Therapy Market, By Retroviral vectors, 2020-2034 (USD Million)
  • Table 89 Italy Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 90 Italy Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 91 Italy Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 92 Spain Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 93 Spain Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 94 Spain Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 95 Spain Gene Therapy Market, By Retroviral Vector, 2020-2034 (USD Million)
  • Table 96 Spain Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 97 Spain Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 98 Spain Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 99 Netherlands Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 100 Netherlands Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 101 Netherlands Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 102 Netherlands Gene Therapy Market, By Retroviral vectors, 2020-2034 (USD Million)
  • Table 103 Netherlands Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 104 Netherlands Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 105 Netherlands Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 106 Austria Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 107 Austria Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 108 Austria Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 109 Austria Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 110 Austria Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 111 Austria Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 112 Austria Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 113 Asia Pacific Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 114 Asia Pacific Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 115 Asia Pacific Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 116 Asia Pacific Gene Therapy Market, By Retroviral vectors, 2020-2034 (USD Million)
  • Table 117 Asia Pacific Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 118 Asia Pacific Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 119 Asia Pacific Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 120 China Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 121 China Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 122 China Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 123 China Gene Therapy Market, By Retroviral Vector, 2020-2034 (USD Million)
  • Table 124 China Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 125 China Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 126 China Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 127 India Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 128 India Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 129 India Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 130 India Gene Therapy Market, By Retroviral vectors, 2020-2034 (USD Million)
  • Table 131 India Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 132 India Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 133 India Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 134 Japan Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 135 Japan Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 136 Japan Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 137 Japan Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 138 Japan Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 139 Japan Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 140 Japan Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 141 South Korea Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 142 South Korea Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 143 South Korea Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 144 South Korea Gene Therapy Market, By Retroviral vectors, 2020-2034 (USD Million)
  • Table 145 South Korea Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 146 South Korea Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 147 South Korea Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 148 Latin America Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 149 Latin America Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 150 Latin America Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 151 Latin America Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 152 Latin America Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 153 Latin America Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 154 Latin America Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 155 Brazil Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 156 Brazil Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 157 Brazil Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 158 Brazil Gene Therapy Market, By Retroviral vectors, 2020-2034 (USD Million)
  • Table 159 Brazil Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 160 Brazil Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 161 Brazil Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 162 Mexico Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 163 Mexico Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 164 Mexico Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 165 Mexico Gene Therapy Market, By Retroviral Vector, 2020-2034 (USD Million)
  • Table 166 Mexico Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 167 Mexico Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 168 Mexico Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 169 Middle East & Africa Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 170 Middle East & Africa Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 171 Middle East & Africa Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 172 Middle East & Africa Gene Therapy Market, By Retroviral vectors, 2020-2034 (USD Million)
  • Table 173 Middle East & Africa Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 174 Middle East & Africa Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 175 Middle East & Africa Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 176 Saudi Arabia Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 177 Saudi Arabia Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 178 Saudi Arabia Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 179 Saudi Arabia Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 180 Saudi Arabia Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 181 Saudi Arabia Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 182 Saudi Arabia Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)
  • Table 183 UAE Gene Therapy Market, By Therapeutic Area, 2020-2034 (USD Million)
  • Table 184 UAE Gene Therapy Market, By Vector Type, 2020-2034 (USD Million)
  • Table 185 UAE Gene Therapy Market, By Viral Vector, 2020-2034 (USD Million)
  • Table 186 UAE Gene Therapy Market, By Retroviral vectors, 2020-2034 (USD Million)
  • Table 187 UAE Gene Therapy Market, By Non-viral vectors, 2020-2034 (USD Million)
  • Table 188 UAE Gene Therapy Market, By Approach, 2020-2034 (USD Million)
  • Table 189 UAE Gene Therapy Market, By Route of Administration, 2020-2034 (USD Million)

List of Figures

  • Figure 1. Executive Summary
  • Figure 2. Research Methodology: Top Down & Bottom-Up Approach
  • Figure 3. Market by Geography, 2020-2034 (USD Million)
  • Figure 6. Porter's Five Forces
  • Figure 7. PEST Analysis
  • Figure 8. Market by Therapeutic Area
  • Figure 9. Global Gene Therapy Market, By Therapeutic Area, 2024 & 2034 (USD Million)
  • Figure 10. Market by Vector Type
  • Figure 11. Global Gene Therapy Market, By Vector Type, 2024 & 2034 (USD Million)
  • Figure 12. Market by Approach
  • Figure 13. Global Gene Therapy Market, By Approach, 2024 & 2034 (USD Million)
  • Figure 14. Market by Route of Administration
  • Figure 15. Global Gene Therapy Market, By Route of Administration, 2024 & 2034 (USD Million)
  • Figure 16. Gene Therapy Market Assessment, By Geography, 2024 & 2034 (USD Million)